Drug and Medication Analysis & Statistics in the United Kingdom, August 2014 (p3)

You might be interested in: drug, vaccine, smoking cessation, more »

61-90 of about 200 reports

Purchase Reports From Reputable Market Research Publishers

Nilotinib  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Nilotinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Drug and Medication
  • Countries : United Kingdom, United States, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, World
Perampanel  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Perampanel - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

  • Industries : Drug and Medication
  • Countries : United Kingdom, Australia, Canada, Spain, Italy, France, Germany, Japan, Europe, United States
AstraZeneca UK Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AstraZeneca UK Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary AstraZeneca UK Limited (AstraZeneca) is a pharmaceutical company. The company develops and markets medicines. Its products include exenatide prolonged-release suspension for injection, rosuvastatin, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Analgesics Market Analysis in the United Kingdom

Analgesics Market Analysis in the United Kingdom

  • $ 898
  • Industry report
  • May 2014
  • by Euromonitor International

Retail value sales of analgesics in the UK grew 1% in 2010 to reach GBP 533 million. This growth was higher than the increase of just under 1% seen in 2009. Consumers were looking for fast pain relief ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Cough, Cold and Allergy (Hay Fever) Remedies Market Analysis in the United Kingdom

Cough, Cold and Allergy (Hay Fever) Remedies Market Analysis in the United Kingdom

  • $ 898
  • Industry report
  • May 2014
  • by Euromonitor International

In 2010 the cough cold and allergies environment grew by more than 2% in current value terms to reach a value of GBP 637 million. The incidence of cold and flu in 2009/2010 appeared to be lower than in ...

  • Industries : Drug and Medication, Tobacco
  • Countries : United Kingdom
NRT Smoking Cessation Aids Market Analysis in the United Kingdom

NRT Smoking Cessation Aids Market Analysis in the United Kingdom

  • $ 898
  • Industry report
  • May 2014
  • by Euromonitor International

Retail sales of NRT smoking cessation aids in the UK grew by 3% in current value terms in 2010 to reach GBP 111 million. The government’s spending cuts have had an indirect positive influence on the ...

  • Industries : Drug and Medication, Tobacco
  • Countries : United Kingdom
MarketVIEW: Group B Streptococcus

MarketVIEW: Group B Streptococcus

  • $ 4 495
  • Industry report
  • May 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

Group B beta streptococci (GBS) or Streptococcus agalactiae is an encapsulated Gram-positive coccus capable of producing a range of diseases in humans of all age ranges. In the neonate, the bacterium can ...

  • Industries : Drug and Medication
  • Countries : United States, World, Australia, Africa, Brazil, Mexico, Canada, United Kingdom, Spain, Italy, France, Germany, Europe, North America
PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : Italy, Spain, France, Germany, United Kingdom, Europe, World
DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022

DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022

Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022

Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022

CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022

Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
Lidoderm/Versatis (Neuropathic Pain) - Forecast and Market Analysis to 2022

Lidoderm/Versatis (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Lidoderm/Versatis (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : Germany, United States, World, Spain, Italy, France, Europe, United Kingdom
Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022

Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : World, Europe, United States, Spain, Italy, France, Germany, United Kingdom
Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022

Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive ...

  • Industries : Drug and Medication
  • Countries : World, United States, Spain, Italy, France, Germany, Europe, United Kingdom
Eladur (Neuropathic Pain) - Forecast and Market Analysis to 2022

Eladur (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • April 2014
  • by Global Data

Eladur (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
MarketVIEW: Cytomegalovirus (CMV) vaccines

MarketVIEW: Cytomegalovirus (CMV) vaccines

  • $ 4 495
  • Industry report
  • April 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas ...

  • Industries : Drug and Medication
  • Countries : United States, Canada, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available ...

  • Industries : Drug and Medication
  • Countries : Australia, Germany, World, Canada, Spain, Italy, France, Japan, Oceania, New Zealand, Europe, United States, United Kingdom
Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Canada, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Canada, Spain, Italy, France, Germany, United States, United Kingdom, Europe
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

  • $ 10 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became ...

  • Industries : Drug and Medication
  • Countries : World, Australia, Canada, Spain, Italy, United Kingdom, France, Germany, Japan, United States, Europe
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Germany, Spain, Italy, France, World, Europe, United States, United Kingdom, Japan
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : World, United Kingdom, Canada, Spain, Italy, France, Germany, Japan
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation ...

  • Industries : Drug and Medication
  • Countries : Canada, Spain, Italy, France, Germany, World, United States, United Kingdom, Europe, Japan
About 1 200 reports

Download Unlimited Documents from Trusted Public Sources

Smoking Treatment Industry in the UK

  • Smoking Cessation Treatment in Primary Care: Prospective Cohort ...
  • September 2014
    6 pages
  • Smoking Treatme...  

  • United Kingdom  

View report >

2 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Select Products Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.